Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
Outlook Therapeutics trims staff and recalibrates its regulatory strategy after its wet AMD trial falls short, underscoring the …
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
